Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer
- PMID: 33976640
- PMCID: PMC8077539
- DOI: 10.1159/000514146
Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer
Abstract
Acute generalized exanthematous pustulosis (AGEP) is a rare drug-related adverse skin reaction caused mainly by antibiotics. Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used to treat lung cancer. A 69-year-old woman with primary lung cancer (adenocarcinoma, cT3N1M1b, stage IVB) developed erythema and multiple skin pustules on her abdomen and both thighs after 7 weeks of erlotinib treatment. She also had fever and general fatigue. Histological examination of a skin biopsy specimen showed intraepidermal pustules with neutrophil and eosinophil infiltration. She was diagnosed with erlotinib-induced AGEP. AGEP resolved by erlotinib discontinuation and systemic corticosteroid treatment. The lung cancer progressed when erlotinib was discontinued, so afatinib, a second-generation EGFR-TKI, was administrated without any skin adverse effects. Afatinib successfully decreased the lung cancer, and maintained the disease stable for 1 year. Although acneiform rash was the most common skin adverse event caused by EGFR, AGEP rarely occurred. The present case also demonstrated that it is possible to switch agents, from erlotinib to afatinib, even though they have the same pharmacological effects. Although AGEP is a rare drug-related skin disorder, physicians should be aware that erlotinib may induce AGEP.
Keywords: Acute generalized exanthematous pustulosis; Erlotinib; Lung cancer; Skin disorder.
Copyright © 2021 by S. Karger AG, Basel.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures


Similar articles
-
Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report.Case Rep Oncol. 2012 May;5(2):253-9. doi: 10.1159/000338806. Epub 2012 May 23. Case Rep Oncol. 2012. PMID: 22712013 Free PMC article.
-
Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.J Med Case Rep. 2020 Nov 3;14(1):210. doi: 10.1186/s13256-020-02504-8. J Med Case Rep. 2020. PMID: 33138853 Free PMC article.
-
Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer.IJU Case Rep. 2022 Aug 16;5(6):497-500. doi: 10.1002/iju5.12525. eCollection 2022 Nov. IJU Case Rep. 2022. PMID: 36341202 Free PMC article.
-
Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature.J Cutan Med Surg. 2013 Nov-Dec;17(6):414-8. doi: 10.2310/7750.2013.12105. J Cutan Med Surg. 2013. PMID: 24138979 Review.
-
Clinical features, diagnosis and management of cephalosporin-induced acute generalized exanthematous pustulosis.J Clin Pharm Ther. 2022 Dec;47(12):2008-2013. doi: 10.1111/jcpt.13738. Epub 2022 Jul 31. J Clin Pharm Ther. 2022. PMID: 35909299
Cited by
-
Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management.Am J Clin Dermatol. 2023 Jul;24(4):557-575. doi: 10.1007/s40257-023-00779-3. Epub 2023 May 8. Am J Clin Dermatol. 2023. PMID: 37156992 Free PMC article. Review.
-
Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.Front Oncol. 2022 Feb 10;12:804212. doi: 10.3389/fonc.2022.804212. eCollection 2022. Front Oncol. 2022. PMID: 35223483 Free PMC article. Review.
-
Acute generalized exanthematous pustulosis induced by icotinib: a case report and literature review.Front Pharmacol. 2024 Aug 30;15:1462430. doi: 10.3389/fphar.2024.1462430. eCollection 2024. Front Pharmacol. 2024. PMID: 39281279 Free PMC article.
-
Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.J Clin Med. 2022 Jan 13;11(2):397. doi: 10.3390/jcm11020397. J Clin Med. 2022. PMID: 35054090 Free PMC article. Review.
References
-
- Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127((9)):1333–8. - PubMed
-
- Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol. 2001;28((3)):113–9. - PubMed
-
- Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73((5)):843–8. - PubMed
-
- Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR) Br J Dermatol. 2007;157((5)):989–96. - PubMed
-
- Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;((5)):CD010383. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous